 Timothy Waxweiler
Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Four-Dimensional Computed Tomography | 3 | 2021 | 27 | 0.770 |
Why?
| | Pulmonary Ventilation | 3 | 2021 | 74 | 0.630 |
Why?
| | Brain Neoplasms | 4 | 2023 | 984 | 0.610 |
Why?
| | Re-Irradiation | 1 | 2016 | 8 | 0.560 |
Why?
| | Lung Neoplasms | 4 | 2023 | 2199 | 0.470 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 4 | 2021 | 119 | 0.450 |
Why?
| | Sarcoma | 1 | 2015 | 138 | 0.440 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 935 | 0.410 |
Why?
| | Radiotherapy, Intensity-Modulated | 3 | 2018 | 125 | 0.400 |
Why?
| | Radiotherapy, Conformal | 3 | 2017 | 68 | 0.390 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 863 | 0.380 |
Why?
| | Prostatic Neoplasms | 5 | 2015 | 925 | 0.360 |
Why?
| | Radiation Pneumonitis | 2 | 2021 | 26 | 0.350 |
Why?
| | Head and Neck Neoplasms | 2 | 2022 | 436 | 0.270 |
Why?
| | Risk Assessment | 1 | 2015 | 2973 | 0.260 |
Why?
| | SEER Program | 6 | 2015 | 196 | 0.260 |
Why?
| | Oncogene Addiction | 1 | 2023 | 5 | 0.220 |
Why?
| | Antineoplastic Agents | 3 | 2023 | 1895 | 0.200 |
Why?
| | Neoplasm Staging | 4 | 2018 | 1176 | 0.180 |
Why?
| | Radiosurgery | 1 | 2022 | 302 | 0.170 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2023 | 398 | 0.170 |
Why?
| | Papillomavirus Infections | 1 | 2022 | 262 | 0.160 |
Why?
| | Proto-Oncogene Proteins | 1 | 2023 | 610 | 0.160 |
Why?
| | Carcinoma, Renal Cell | 1 | 2021 | 173 | 0.160 |
Why?
| | Treatment Outcome | 8 | 2023 | 9089 | 0.150 |
Why?
| | Smokers | 1 | 2018 | 128 | 0.150 |
Why?
| | Kidney Neoplasms | 1 | 2021 | 333 | 0.140 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2016 | 40 | 0.140 |
Why?
| | Neoplasm Grading | 2 | 2014 | 242 | 0.140 |
Why?
| | Salivary Gland Neoplasms | 1 | 2016 | 31 | 0.140 |
Why?
| | Respiration | 1 | 2017 | 179 | 0.130 |
Why?
| | Prognosis | 4 | 2018 | 3334 | 0.130 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 62 | 0.130 |
Why?
| | Analysis of Variance | 2 | 2015 | 1226 | 0.120 |
Why?
| | Retrospective Studies | 6 | 2017 | 12515 | 0.120 |
Why?
| | Testicular Neoplasms | 1 | 2016 | 97 | 0.120 |
Why?
| | Organ Sparing Treatments | 1 | 2015 | 31 | 0.120 |
Why?
| | Medically Uninsured | 1 | 2015 | 122 | 0.120 |
Why?
| | Brachytherapy | 1 | 2015 | 104 | 0.120 |
Why?
| | Oligodendroglioma | 1 | 2014 | 15 | 0.120 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 973 | 0.120 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2014 | 182 | 0.110 |
Why?
| | Astrocytoma | 1 | 2014 | 108 | 0.110 |
Why?
| | Insurance, Health | 1 | 2015 | 244 | 0.110 |
Why?
| | Humans | 19 | 2023 | 114756 | 0.110 |
Why?
| | Aged | 11 | 2023 | 19094 | 0.110 |
Why?
| | Infant | 2 | 2016 | 7935 | 0.110 |
Why?
| | Male | 15 | 2023 | 55579 | 0.100 |
Why?
| | Child, Preschool | 2 | 2016 | 9079 | 0.100 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2013 | 67 | 0.100 |
Why?
| | Benzimidazoles | 1 | 2013 | 138 | 0.100 |
Why?
| | Eye Abnormalities | 1 | 2011 | 10 | 0.100 |
Why?
| | Retinol-Binding Proteins | 1 | 2011 | 13 | 0.100 |
Why?
| | Chemoradiotherapy | 1 | 2013 | 190 | 0.100 |
Why?
| | Medicaid | 1 | 2015 | 407 | 0.100 |
Why?
| | Survival Rate | 4 | 2016 | 1642 | 0.100 |
Why?
| | Lymph Nodes | 1 | 2014 | 423 | 0.100 |
Why?
| | Adolescent | 4 | 2016 | 17808 | 0.090 |
Why?
| | Eye Proteins | 1 | 2011 | 71 | 0.090 |
Why?
| | Eye | 1 | 2011 | 101 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1361 | 0.090 |
Why?
| | Algorithms | 1 | 2017 | 1468 | 0.090 |
Why?
| | Neoplasm Proteins | 1 | 2013 | 385 | 0.090 |
Why?
| | Middle Aged | 10 | 2023 | 26757 | 0.080 |
Why?
| | Melanoma | 1 | 2015 | 629 | 0.080 |
Why?
| | Prospective Studies | 2 | 2018 | 6217 | 0.080 |
Why?
| | Adult | 7 | 2023 | 30548 | 0.080 |
Why?
| | United States | 5 | 2015 | 12176 | 0.080 |
Why?
| | Skin Neoplasms | 1 | 2015 | 761 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 3 | 2015 | 815 | 0.080 |
Why?
| | Young Adult | 3 | 2016 | 10463 | 0.070 |
Why?
| | Child | 2 | 2016 | 18352 | 0.070 |
Why?
| | Radiotherapy Dosage | 2 | 2018 | 245 | 0.070 |
Why?
| | Colorectal Neoplasms | 1 | 2013 | 621 | 0.070 |
Why?
| | Female | 9 | 2023 | 59507 | 0.070 |
Why?
| | Propensity Score | 2 | 2016 | 224 | 0.060 |
Why?
| | Infant, Newborn | 1 | 2015 | 5035 | 0.060 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 528 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2016 | 4420 | 0.050 |
Why?
| | Prostate-Specific Antigen | 2 | 2014 | 153 | 0.050 |
Why?
| | Proportional Hazards Models | 2 | 2015 | 1080 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2016 | 6350 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 2 | 2023 | 3039 | 0.050 |
Why?
| | Central Nervous System | 1 | 2023 | 237 | 0.050 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 305 | 0.050 |
Why?
| | ErbB Receptors | 1 | 2023 | 560 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 718 | 0.040 |
Why?
| | Age Factors | 2 | 2016 | 2890 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 30 | 0.040 |
Why?
| | Phthalazines | 1 | 2018 | 38 | 0.040 |
Why?
| | Cetuximab | 1 | 2018 | 91 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 372 | 0.040 |
Why?
| | Piperazines | 1 | 2018 | 311 | 0.030 |
Why?
| | Skin Ulcer | 1 | 2015 | 13 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1122 | 0.030 |
Why?
| | Radiation Protection | 1 | 2015 | 34 | 0.030 |
Why?
| | Marital Status | 1 | 2014 | 41 | 0.030 |
Why?
| | Disease Progression | 1 | 2021 | 2387 | 0.030 |
Why?
| | Time Factors | 2 | 2014 | 6124 | 0.030 |
Why?
| | Prostatectomy | 1 | 2014 | 98 | 0.030 |
Why?
| | Comet Assay | 1 | 2013 | 18 | 0.030 |
Why?
| | HT29 Cells | 1 | 2013 | 36 | 0.030 |
Why?
| | Organoplatinum Compounds | 1 | 2013 | 37 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2014 | 280 | 0.030 |
Why?
| | Radiotherapy | 1 | 2014 | 176 | 0.030 |
Why?
| | HCT116 Cells | 1 | 2013 | 71 | 0.030 |
Why?
| | Transcriptome | 1 | 2018 | 727 | 0.030 |
Why?
| | Research Design | 1 | 2018 | 931 | 0.030 |
Why?
| | Camptothecin | 1 | 2013 | 98 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2014 | 623 | 0.030 |
Why?
| | Fluorouracil | 1 | 2013 | 152 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2015 | 737 | 0.020 |
Why?
| | Tumor Burden | 1 | 2013 | 261 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2018 | 1053 | 0.020 |
Why?
| | Glioblastoma | 1 | 2014 | 253 | 0.020 |
Why?
| | Microscopy, Interference | 1 | 2011 | 9 | 0.020 |
Why?
| | Refractive Errors | 1 | 2011 | 13 | 0.020 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 2011 | 14 | 0.020 |
Why?
| | Mice, Nude | 1 | 2013 | 635 | 0.020 |
Why?
| | S Phase | 1 | 2011 | 70 | 0.020 |
Why?
| | DNA Damage | 1 | 2013 | 357 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2013 | 706 | 0.020 |
Why?
| | Organ Size | 1 | 2011 | 435 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2011 | 305 | 0.020 |
Why?
| | Sex Factors | 1 | 2014 | 1717 | 0.020 |
Why?
| | Lung | 1 | 2021 | 3546 | 0.020 |
Why?
| | Histones | 1 | 2013 | 536 | 0.020 |
Why?
| | Mice | 2 | 2013 | 14916 | 0.020 |
Why?
| | Colorado | 1 | 2015 | 4086 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 4409 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2011 | 2582 | 0.020 |
Why?
| | Apoptosis | 1 | 2011 | 2369 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 4710 | 0.010 |
Why?
| | Animals | 2 | 2013 | 31761 | 0.010 |
Why?
|
|
Waxweiler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|